Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Nakashima, Hiroshi; Nakamura, Takemi; Kobayashi, Hitoshi*; Tanaka, Susumu*; Kumada, Hiroaki*
NEA/NSC/R(2021)2 (Internet), p.142 - 151, 2021/12
Aiming of development of facilities for boron neutron capture therapy (BNCT) that can be installed in hospitals, an accelerator-based BNCT facility is being developed at the Ibaraki Neutron Medical Research Center under a collaboration among the Japan Atomic Energy Agency, the High Energy Accelerator Research Organization, the University of Tsukuba, and other institutions. It consists of a proton accelerator, having a maximum beam power of 80 kW, and a target, moderator, collimator and shield (TMCS) system. For the design concept, to satisfy the BNCT beam conditions and achieve a low activation, the radiation behavior in the TMCS system was simulated by the Monte Carlo method and this system configuration was optimized accordingly. In addition, the radiation estimation of the TMCS system was verified via several experiments and its applicability for BNCT was proved. This report reviews the estimation and validation studies for the development of the accelerator-based BNCT facility.
Shibata, Takanori*; Sugimura, Takashi*; Ikegami, Kiyoshi*; Takagi, Akira*; Sato, Masaharu*; Naito, Fujio*; Okoshi, Kiyonori; Hasegawa, Kazuo
JPS Conference Proceedings (Internet), 33, p.011009_1 - 011009_6, 2021/03
Upgrade of beam current in the Linac of Ibaraki Boron Neutron Capture Therapy (iBNCT) is one of the most important requirements to realize clinical trial. By 2018, the measurement of the produced neutrons characteristics and the neutron irradiation experiment for living cells have been done by producing 8-MeV proton beam current at the beryllium target with average current up to 2 mA. In order to satisfy the original clinical trial conditions, 5 mA average beam current is required at the target. For this goal, peak beam current extracted from the ion source should be increased to 60 mA from the present 30 mA with duty factor up to more than 10% (pulse width up to 1 ms and repetition rate up to more than 100 Hz). Stability of the peak current in the macro pulse is also important for the clinical application.
Ikebe, Yurie*; Oshima, Masumi*; Bamba, Shigeru*; Asai, Masato; Tsukada, Kazuaki; Sato, Tetsuya; Toyoshima, Atsushi*; Bi, C.*; Seto, Hirofumi*; Amano, Hikaru*; et al.
Applied Radiation and Isotopes, 164, p.109106_1 - 109106_7, 2020/10
Times Cited Count：2 Percentile：24.28(Chemistry, Inorganic & Nuclear)Boron Neutron Capture Therapy (BNCT) is a radiotherapy for the treatment of intractable cancer. In BNCT precise determination of 
B concentration in whole blood sample before neutron irradiation is crucial for control of the neutron irradiation time and the neutron dosimetry. We have applied the Charged Particle Activation Analysis (CPAA) to non-destructive and accurate determination of B concentration in whole blood sample. The experiment was performed at JAEA Tandem Accelerator using an 8 MeV proton beam. The 478 keV 
ray of 
Be produced in the B(p,
)Be reaction was used to quantify the B, and rays of 
Co originating from the reaction with Fe in blood was used to normalize the -ray intensity. The results demonstrated that the present CPAA method can be applied to the determination of the B concentration in the blood sample.
Naito, Fujio*; Anami, Shozo*; Ikegami, Kiyoshi*; Uota, Masahiko*; Ouchi, Toshikatsu*; Onishi, Takahiro*; Oba, Toshiyuki*; Obina, Takashi*; Kawamura, Masato*; Kumada, Hiroaki*; et al.
Proceedings of 13th Annual Meeting of Particle Accelerator Society of Japan (Internet), p.1244 - 1246, 2016/11
The proton linac installed in the Ibaraki Neutron Medical Research Center is used for production of the intense neutron flux for the Boron Neutron Capture Therapy (BNCT). The linac consists of the 3-MeV RFQ and the 8-MeV DTL. Design average beam current is 10mA. Target is made of Beryllium. First neutron production from the Beryllium target was observed at the end of 2015 with the low intensity beam as a demonstration. After the observation of neutron production, a lot of improvement s was carried out in order to increase the proton beam intensity for the real beam commissioning. The beam commissioning has been started on May 2016. The status of the commissioning is summarized in this report.
Ishiyama, Shintaro; Imahori, Yoshio*; Itami, Jun*; Koivunoro, H.*
Global Journal of Medical Research; F, 15(4), p.1 - 5, 2015/11
In defining the biological effects of the neutron capture reaction, we have proposed a deterministic parsing model (ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness (CBE) factor in Borono-Phenyl-Alanine (BPA)-mediated Boron Neutron Capture Therapy (BNCT). To determine the CBE factor, we derived new calculation formula founded on the deterministic parsing model with three constants, CBE0, F, n and the eigen value Nth/Nmax. where, Nth and Nmax are the threshold value of boron concentration of N and saturation boron density. In order to determine Nth and Nmax in the formula, sigmoid logistic function was employed for B concentration data, Db(t) obtained by dynamic PETtechnique, where, A, a and t0 are constants. From the application of sigmoid function to dynamic PET data, it is concluded that the Nth and Nmax for tissue and tumor are identified with the parameter constants in the sigmoid function in tion as: th b at 0 and max N = D t = N = x.
Ishiyama, Shintaro; Imahori, Yoshio*; Itami, Jun*; Koivunoro, H.*
Journal of Cancer Therapy, 6(8), p.759 - 766, 2015/08
From the concentration of 10BPA drug was intravenously injected into the tumor and normal cells of brain tumor patients measured by dynamic PET method, the CBE factor for the BNCT treatment can be calculated by using ISHIYAMA-IMAHORI model.
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Yamamoto, Tetsuya*; Nakai, Kei*; Nakagawa, Yoshinobu*; Kageji, Teruyoshi*; Matsumura, Akira*
Applied Radiation and Isotopes, 61(5), p.1045 - 1050, 2004/11
Times Cited Count：12 Percentile：61.53(Chemistry, Inorganic & Nuclear)To carry out the BNCT clinical trials based on accurate dosimetry of several absorbed doses given to a patient, we have developed JCDS which can determine the absorbed doses by numerical simulation. The aim of this study is to improve the accuracy of the BNCT dosimetry efficiently. We have developed the multi-voxel calculation method reconstructing the original voxel model by combining of several voxel cell sizes such as in 5mm, 10mm and 20mm voxel cell. To verify the accuracy of the multi-voxel method, the calculation results were compared with the phantom experimental data. These results proved that the multi-voxel calculation enables JCDS to more accurately estimate the absorbed doses to a patient by efficient calculations.
Kageji, Teruyoshi*; Nagahiro, Shinji*; Mizobuchi, Keiji*; Toi, Hiroyuki*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Applied Radiation and Isotopes, 61(5), p.1063 - 1067, 2004/11
Times Cited Count：9 Percentile：52.68(Chemistry, Inorganic & Nuclear)no abstracts in English
Yamamoto, Tetsuya*; Matsumura, Akira*; Nakai, Kei*; Shibata, Yasushi*; Endo, Kiyoshi*; Sakurai, Fumio; Kishi, Toshiaki; Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya
Applied Radiation and Isotopes, 61(5), p.1089 - 1093, 2004/11
Times Cited Count：54 Percentile：94.65(Chemistry, Inorganic & Nuclear)no abstracts in English
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya; Matsumura, Akira*; Nakagawa, Yoshinobu*
Japanese Journal of Medical Physics, Vol.23, Supplement 3, p.292 - 295, 2003/09
no abstracts in English
Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya; Matsumura, Akira*; Yamamoto, Tetsuya*; Nose, Tadao*; Nakagawa, Yoshinobu*; Kageji, Teruyoshi*; Uchiyama, Junzo
JAERI-Tech 2003-002, 49 Pages, 2003/03
JAERI-Tech-2003-002.pdf:5.22MB
no abstracts in English
Kumada, Hiroaki; Matsumura, Akira*; Nakagawa, Yoshinobu*; Yamamoto, Tetsuya*; Yamamoto, Kazuyoshi; Torii, Yoshiya
Research and Development in Neutron Capture Therapy, p.529 - 534, 2002/09
no abstracts in English
Kumada, Hiroaki; Kishi, Toshiaki; Hori, Naohiko; Yamamoto, Kazuyoshi; Torii, Yoshiya
Research and Development in Neutron Capture Therapy, p.115 - 119, 2002/09
no abstracts in English
Yamamoto, Tetsuya*; Matsumura, Akira*; Yamamoto, Kazuyoshi; Kumada, Hiroaki; Torii, Yoshiya; Endo, Kiyoshi*; Matsushita, Akira*; Shibata, Yasushi*; Nose, Tadao*
Research and Development in Neutron Capture Therapy, p.415 - 418, 2002/09
Dose measurements in a patient's brain undergoing intraoperative BNCT (IOBNCT) were compared with calculations by a JAERI computational dosimetry system (JCDS). The maximum thermal neutron flux on the brain surface from the postirradiation measurement averaged 2.33
0.37(
10
cm
s
) and the vascular boron dose averaged 11.41.2 (9.6-12.7) Gy. Using JCDS, the maximum thermal neutron flux in the irradiated volume averaged 2.210.33(10cms), while the target vascular dose averaged 5.7 Gy and varied from 3.5 to 7.8 Gy. As such, in the dose planning for intra-operative irradiation, practical use of JCDS is recommended for uniform volume-dose control of postsurgical brain in IOBNCT.
Nakai, Kei*; Matsumura, Akira*; Yamamoto, Tetsuya*; Shibata, Yasushi*; Zhang, T.*; Akutsu, Hiroyoshi*; Matsuda, M.*; Matsushita, Akira*; Yasuda, Susumu*; Takano, Shingo*; et al.
Research and Development in Neutron Capture Therapy, p.1135 - 1138, 2002/09
7 patients have been undergoing Intraoperative boron neutron capture therapy (IOBNCT) for malignant glioma at Japan Atomic Energy Institute (JAERI). Post-BNCT MRI studies revealed one local recurrence and two distant recurrences. Distant recurrence is uncommon in the conventional radiation therapy. Symptomatic late radiation necrosis occurred in one case.
Matsushita, Akira*; Yamamoto, Tetsuya*; Matsumura, Akira*; Nose, Tadao*; Yamamoto, Kazuyoshi; Kumada, Hiroaki; Torii, Yoshiya; Kashimura, Takanori*; Otake, Shinichi*
Research and Development in Neutron Capture Therapy, p.141 - 143, 2002/09
A thermal-epithermal mixed beam "Thermal Neutron Beam Mode I" was used in the eleven sessions of boron neutron capture therapy which have been performed at JRR-4 from 1998. We are planning to use an epithermal beam for the treatment of deeper tumors in the next trial of the intraoperative BNCT. In this study, "Epi-12" which was made by putting up a cadmium shutter of "Thermal Neutron Beam Mode I" was investigated for the clinical benefits and safety by epithermal beams. Decrease of fast neutron contamination ratio in Epi-12 mode is the advantage for BNCT, particular in the intraoperative BNCT. Because fast neutron on the brain surface is one of the critical factors in the intraoperative BNCT in which the plain beam directly interacts the normal structures. Furthermore a mixture of mode Epi-12 and Th-12 will provide various dose distribution designs. It may be used as a new method to control the best distribution for individual tumors.
Nakagawa, Yoshinobu*; Pooh, K. H.*; Kageji, Teruyoshi*; Uyama, Shinichi*; Kobayashi, Toru*; Sakurai, Yoshinori*; Matsumura, Akira*; Yamamoto, Tetsuya*; Kumada, Hiroaki
Research and Development in Neutron Capture Therapy, p.1113 - 1116, 2002/09
To make a new protocol using epithermal neutron beam for high-grade glioma patients, we elucidated the relationship between the radiation dose, histological tumor grade, and clinical outcome. One hundred and eighty-three patients with kinds of brain tumors were treated by BNCT since 1968, however, we performed a retrospective study of 105 patients with glial tumors treated in Japan between 1978 and 1997. As for the radiation side effect, we analyzed all patients(n=159) treated between 1977 and 2001. Ten patients with glioblastoma were treated according to the new protocol using epithermal neutron.
Kumada, Hiroaki; Matsumura, Akira*; Nakagawa, Yoshinobu*
Nihon Genshiryoku Gakkai Wabun Rombunshi, 1(1), p.59 - 68, 2002/03
no abstracts in English
Department of Research Reactor
JAERI-Conf 2001-017, 397 Pages, 2001/11
JAERI-Conf-2001-017.pdf:46.89MB
no abstracts in English
